GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Current Accrued Expense

Y-Biologics (XKRX:338840) Current Accrued Expense : ₩0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Current Accrued Expense?

Y-Biologics's Current Accrued Expense for the quarter that ended in Mar. 2024 was ₩0 Mil.


Y-Biologics Current Accrued Expense Historical Data

The historical data trend for Y-Biologics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Current Accrued Expense Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

Y-Biologics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only - - - - -

Y-Biologics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Y-Biologics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-Biologics (XKRX:338840) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines